Company Snapshot

Investment Thesis

AbbVie is navigating the post-Humira landscape by scaling immunology blockbusters Skyrizi and Rinvoq, layering in neuroscience cash flows, and sustaining a top-tier dividend. High-margin therapeutics and disciplined capital allocation underpin durable EPS and free cash flow growth.

  • Immunology Engine: Skyrizi and Rinvoq are compounding above 30% and are positioned to exceed Humira revenue by 2026.
  • Pipeline Depth: Neuroscience programs such as Vraylar, Qulipta, and Ubrelvy extend growth into large, underpenetrated indications.
  • Shareholder Returns: AbbVie couples mid-single-digit revenue growth with a 50-year dividend growth track record and rapid deleveraging post-Allergan.

Portfolio Mix

Immunology 57% of FY24 revenue
Hematologic Oncology 19% — Imbruvica, Venclexta
Neuroscience 11% — Vraylar, migraine portfolio
Aesthetics & Eye Care 13% — Botox, Juvederm, Allergan brands

Mix reflects AbbVie fiscal year 2024 segment reporting.

Recent Performance

MTD -0.87%
QTD -11.55%
YTD +20.46%
5Y +128.73%

Shares pulled back to $228 after a strong summer rally as investors digested near-term gross margin compression, yet AbbVie remains up 27% year to date on the strength of immunology growth and better-than-feared Humira erosion.

Strategic Insights

Post-Humira Transition

Skyrizi and Rinvoq adoption in psoriasis, Crohn’s, and ulcerative colitis offsets Humira declines and expands AbbVie’s immunology moat.

Neuroscience Upside

Vraylar augmentation and migraine launches (Qulipta, Ubrelvy) diversify revenue and extend patent lives into the 2030s.

Aesthetics Platform

Botox and Juvederm maintain leadership in cash-pay procedures, supporting premium margins and optionality for new launches like Daxxify.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...